A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
Status:
Completed
Trial end date:
2016-07-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of TAK-063
compared with placebo in treatment of acutely exacerbated schizophrenia.